Royalty Rates in Biotech Deals, Part I
Royalty rates in biotech deals are determined by a variety of factors; most important is the level of risk the product represents at the stage it is licensed.
You may also be interested in...
Sandoz is benefiting from its focus on a “pure play” generics and biosimilars model that is unique among its peers, CEO Richard Saynor tells Generics Bulletin in an exclusive interview.
The dispute over a likely 60% reduction in supplies of AstraZeneca's COVID-19 vaccine shows no sign of resolution.
In December, a California federal court ordered the US Environmental Protection Agency to amend its TSCA Chemical Data Reporting rule to address asbestos information-gathering “loopholes,” including a current exemption for asbestos that occurs as an impurity in raw materials such as cosmetic talc.